{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002737227,0.0005462312,0.001503532,0.001078829,0.0002286089,0.001318948,0.001034491,0.0009670343,0.003834896],"category_scores_gemma":[0.003575833,0.0002924694,0.001459532,0.001042192,0.0003187818,0.001490877,0.0007413438,0.003003652,0.001451439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001347079,"about_ca_system_score_gemma":0.00171213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001281668,"about_ca_topic_score_gemma":0.005136123,"domain_scores_codex":[0.9993716,0.0001397504,0.0001485214,0.00006242382,0.0001852745,0.00009247824],"domain_scores_gemma":[0.9979778,0.0009352464,0.0004028383,0.00006043402,0.0004702925,0.0001534465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001430063,0.0001315958,0.000895388,0.005622956,0.0003844807,0.0001103372,0.00004346621,0.0003352713,0.0019764,0.0008640785,0.0423771,0.9458289],"study_design_scores_gemma":[0.00201872,0.002512673,0.008560107,0.01138935,0.002917128,0.001384674,0.00008400313,0.0007298266,0.002840549,0.001899066,0.9655876,0.0000761807],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.005415077,0.9750404,0.0009281535,0.006647951,0.003241121,0.0001091355,0.0006602393,0.00008561202,0.007872289],"genre_scores_gemma":[0.03009553,0.9433768,0.003284345,0.01326908,0.003676728,0.0002254525,0.002102233,0.00006164375,0.003908273],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.003834896,"threshold_uncertainty_score":0.014476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008401937325614091,"score_gpt":0.2975276717874244,"score_spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}